Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825961 | 1.00 | MGLL (0.55) | MGLLCNR2TRPV1CNR1DGKA | |
| SCHEMBL6825958 | 1.00 | MGLL (0.55) | MGLLCNR2TRPV1CNR1DGKA | |
| SCHEMBL9956940 | 0.91 | FAAH (0.52) | FAAHEPHX2 | |
| SCHEMBL13949564 | 0.91 | FAAH (0.46) | FAAH | |
| SCHEMBL27956216 | 0.91 | CA1 (0.50) | DGKAFAAH | |
| SCHEMBL2562127 | 0.91 | CA1 (0.50) | DGKAFAAH | |
| SCHEMBL28802095 | 0.91 | CA1 (0.50) | DGKAFAAH | |
| SCHEMBL13471573 | 0.91 | CA1 (0.50) | DGKAFAAH | |
| SCHEMBL17921025 | 0.89 | CA1 (0.52) | MGLLFAAH | |
| SCHEMBL16718899 | 0.87 | DUSP3 (0.50) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423066-B2 | Dietetics; use in treatment of obesity, for reducing body weight, modulating body lipid metabolism, and reducing food intake | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2004034968-A2 | COMBINATION THERAPY FOR CONTROLLING APPETITES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004034968-A2 | COMBINATION THERAPY FOR CONTROLLING APPETITES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | MGLL 48/4885CNR2 2/4885TRPV1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.